Save as Favorite
Sign in to receive recommendations (Learn more)

Kisqali (chemical name: ribociclib, formerly called LEE011) was approved by the U.S. Food and Drug Administration (FDA) on March 13, 2017 to be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in postmenopausal women. Kisqali is a pill taken by mouth.

In this section you can learn more about:

Was this article helpful? Yes / No

Bco internal cc1718 banner miniad final
Back to Top